Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05 2023 - 8:30AM
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”
or the “Company”), a clinical-stage biopharmaceutical
company focused on developing therapies for the treatment and
prevention of addiction and related disorders, today announced that
Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating
in the H.C. Wainwright 25th Annual Global Investment Conference
being held September 11-13, 2023 at the Lotte New York Palace Hotel
in New York City.
Adial’s presentation will be available on-demand
to registered attendees via the conference platform beginning
Monday, September 11, 2023 at 7:00 AM Eastern Time. A webcast of
the Company’s presentation can also be accessed at
https://journey.ct.events/view/6c629ed5-e972-4394-9166-605c9967f5ff
and on the investor relations section of company Adial’s website at
https://www.adial.com/investors/.
Management will be participating in one-on-one
meetings with qualified members of the investor community
throughout the conference in New York City. To request a meeting,
please contact adil@crescendo-ir.com.
About Adial Pharmaceuticals,
Inc.Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the development of treatments
for addictions and related disorders. The Company’s lead
investigational new drug product, AD04, is a genetically targeted,
serotonin-3 receptor antagonist, therapeutic agent for the
treatment of Alcohol Use Disorder (AUD) in heavy drinking patients
and was recently investigated in the Company’s ONWARD™ pivotal
Phase 3 clinical trial for the potential treatment of AUD in
subjects with certain target genotypes (estimated to be
approximately one-third of the AUD population) identified using the
Company’s companion diagnostic genetic test. ONWARD showed
promising results in reducing drinking in heavy drinking patients,
and no overt safety or tolerability concerns. AD04 is also believed
to have the potential to treat other addictive disorders such as
Opioid Use Disorder, gambling, and obesity. Additional information
is available at www.adial.com.
Contact:
Crescendo Communications, LLCDavid Waldman / Alexandra
SchiltTel: 212-671-1020Email: adil@crescendo-ir.com
Adial Pharmaceuticals (NASDAQ:ADILW)
Historical Stock Chart
From Jul 2024 to Aug 2024
Adial Pharmaceuticals (NASDAQ:ADILW)
Historical Stock Chart
From Aug 2023 to Aug 2024